← Leaderboards
Robert R Luedtke
University Of North Texas Hlth Sci Ctr
$6,651,314
Attributed
$6,651,314
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $749.3K · FY2007–20$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$6,651,314 · 4
By mechanism
R01$6,651,314 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Affinity”
- Dennis R. Burton · Scripps Research Institute$64,397,776
- James E Crowe · Vanderbilt University Medical Center$53,471,415
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$45,445,140
- Timothy A Springer · Boston Children'S Hospital$41,593,445
- Misty Ward Stevens · Intervexion Therapeutics, Llc$38,187,594
- Rafi Ahmed · Emory University$36,776,987
Research focus
AffinityPharmaceutical PreparationsIn VivoPropertyEvaluationBaseReceptorPsychological ReinforcementPlayRattusDesignPathway InteractionsCocaineAgonistGenerationsBehavioralAdenylate CyclasePiperazinesBehaviorDopamine D3 ReceptorIn VitroResponseAttenuatedRewards
Grant awards (20)
Discovery of functionally selective Alzheimer's disease therapeutics$749,313
R01 · FY2020 · AG · contact PI
Discovery of functionally selective Alzheimer's disease therapeutics$544,576
R01 · FY2019 · AG · contact PI
Discovery of functionally selective Alzheimer's disease therapeutics$551,284
R01 · FY2018 · AG · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$636,340
R01 · FY2017 · DA · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$633,194
R01 · FY2016 · DA · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$677,268
R01 · FY2015 · DA · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$394,393
R01 · FY2011 · DA · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$423,289
R01 · FY2010 · DA · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$38,760
R01 · FY2010 · DA · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$416,990
R01 · FY2009 · DA · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$30,450
R01 · FY2009 · DA · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$419,213
R01 · FY2008 · DA · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$30,000
R01 · FY2008 · DA · contact PI
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse$431,268
R01 · FY2007 · DA · contact PI
Mapping the D2/D3 Dopamine Receptor Binding Sites$170,734
R01 · FY2004 · DA
Mapping the D2/D3 Dopamine Receptor Binding Sites$135,235
R01 · FY2003 · DA
Mapping the D2/D3 Dopamine Receptor Binding Sites$35,499
R01 · FY2003 · DA
Mapping the D2/D3 Dopamine Receptor Binding Sites$135,235
R01 · FY2002 · DA
Mapping the D2/D3 Dopamine Receptor Binding Sites$135,235
R01 · FY2001 · DA
THERAPEUTICS FOR COCAINE DEPENDENCE--NATURAL PRODUCTS$63,038
R01 · FY2000 · DA